Structural identification of the RY12 domain of RyR1 as an ADP sensor and the target of the malignant hyperthermia therapeutic dantrolene

Oliver B. Clarke, Kookjoo Kim, Huan Li, Yuan Qi, Zephan Melville, Ran Zalk, Amédée des Georges, Joachim Frank, Wayne A. Hendrickson, Andrew R. MarksResearch Square 2024 · DOI

Introduction

The Ryanodine Receptor 1 (RyR1) is a critical calcium release channel in skeletal muscle. Mutations in RyR1 can lead to Malignant Hyperthermia (MH), a life-threatening condition where volatile anesthetics trigger uncontrolled calcium release, causing muscle rigidity and hyperthermia. While dantrolene has been the gold-standard treatment for MH for decades, its precise binding site and inhibitory mechanism remained elusive. This study utilizes high-resolution cryo-electron microscopy (cryo-EM) to define the structural basis of dantrolene action and uncovers a novel metabolic sensing role for the RY12 domain.

Methodology

Researchers employed single-particle cryo-EM to visualize RyR1 in various ligand-bound states, achieving resolutions between 2.2 Å and 2.6 Å through local refinement of peripheral domains. These structural findings were validated using planar lipid bilayer recordings to measure channel open probability ($P_o$) and site-directed mutagenesis (specifically the W882A mutation) to confirm the functional relevance of the identified binding pockets.

Results

The Dantrolene Binding Site and RY12 Domain

The study reveals that dantrolene does not bind to RyR1 in isolation but rather forms a ternary complex, stacking directly against a molecule of ATP or ADP within the RY12 domain. This "sandwich" arrangement is essential; functional assays demonstrated that dantrolene inhibition is strictly dependent on the presence of these nucleotides.

Structural overview of RyR1 showing the binding sites for dantrolene, nucleotides, and 4CmC.

The binding induces a conformational change in the RY12 domain, which acts as a molecular clamp. This movement is allosterically coupled to the closure of the central pore, effectively shutting down the "leaky" channel characteristic of MH. Key residues, such as W882 and W996, were identified as critical for stabilizing this drug-nucleotide interaction. The W882A mutation was shown to completely abolish the inhibitory effect of dantrolene, providing functional confirmation of the structural model.

RY12 as a Metabolic Sensor

Beyond its role as a drug target, the RY12 domain was found to selectively bind two ADP molecules in the absence of dantrolene. This suggests that the domain functions as a natural sensor for the cellular ATP/ADP ratio. In conditions of metabolic stress or muscle fatigue where ADP levels rise, this site binds ADP to dampen RyR1 activity, serving as a "metabolic brake" to preserve cellular energy.

Mechanisms of MH Triggers

The researchers also mapped the binding sites for 4-chloro-m-cresol (4CmC), a known MH trigger. 4CmC was found to occupy "cryptic" pockets within the core solenoid and transmembrane domains. These sites are typically hidden, suggesting that the channel must undergo specific conformational shifts to allow trigger agents to access these pockets and activate the receptor.

Conclusion

By providing an atomic-level blueprint of the dantrolene binding site, this research resolves a long-standing mystery in muscle pharmacology. The discovery of the RY12 domain's dual role as a therapeutic target and a metabolic sensor opens new avenues for understanding muscle physiology and developing treatments for other RyR-related disorders, such as heart failure. Future work will focus on detailing the full mechanical pathway of allosteric signal transmission from the peripheral RY12 domain to the central pore.

Summary updated

Abstract

<title>Abstract</title> Malignant hyperthermia (MH) is a life-threatening pharmacogenetic condition triggered by volatile anesthetics, which activate pathogenic RyR1 mutants. The small molecule therapeutic dantrolene has long been used to treat MH. However, the binding site and mechanism of dantrolene remain unclear. Here, we present cryo-EM structures of RyR1 bound to dantrolene and the MH trigger agent 4-chloro-m-cresol (4CmC), revealing the dantrolene and 4CmC binding sites in atomic detail. Dantrolene binds stacked with ATP or ADP in the RY12 domain at the corner of the receptor, inducing a conformational change in this domain which is allosterically coupled to pore closure. Functional analyses revealed that ATP or ADP was required for dantrolene inhibition, and a single point mutation that disrupts the peripheral ATP binding site abolished ATP/ADP-dependent dantrolene inhibition. Strikingly, in the absence of dantrolene, this site selectively binds two ADP molecules, suggesting a possible role in ATP/ADP ratio sensing. Structures and maps can be found here: https://www.dropbox.com/scl/fi/elb0vm1evd0y47lnt6mwz/RyR1_maps_and_models.zip?rlkey=0zguve9jievklj1fb9s3mburg&amp;dl=0
BibTeX
@inproceedings{clarke2024structural,
  author = {Oliver B. Clarke and Kookjoo Kim and Huan Li and Yuan Qi and Zephan Melville and Ran Zalk and Amédée des Georges and Joachim Frank and Wayne A. Hendrickson and Andrew R. Marks},
  title = {{Structural identification of the RY12 domain of RyR1 as an ADP sensor and the target of the malignant hyperthermia therapeutic dantrolene}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-5604712/v1},
}
Figure